Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
A switch to a regimen consisting of ATV/RTV 300/100 mg QD + 3TC 300 mg QD in HIV-1 infected
subjects in their first antiretroviral regimen and who are virologically suppressed on a
regimen which consists of 2 NRTIs + any 3rd agent, is non-inferior to continue or switch to
ATV/RTV 300/100 mg QD + 2 optimized NRTIs for maintenance of virological suppression.